Transformation from adenocarcinoma to squamous cell carcinoma associated with long-term administration of EGFR-TKIs.

Transformation from adenocarcinoma to squamous cell carcinoma associated with long-term administration of EGFR-TKIs.
Mol Clin Oncol. 2020 Dec;13(6):82
Authors: Haruki T, Nakanishi A, Matsui S, Kidokoro Y, Kubouchi Y, Takagi Y, Taniguchi Y, Nakamura H
Abstract
Although patients with non-small cell lung cancer exhibiting EGFR mutations generally respond to tyrosine kinase inhibitors (TKIs), the majority of patients acquire resistance ~1 year after treatment. EGFR T790M mutations, MET or HER2 amplifications and phenotypic transformations contribute to the mechanism of EGFR-TKI resistance. The transformation of small cell lung cancer frequently occurs, although few convert to squamous cell carcinoma associated with the administration of EGFR-TKIs. The current study reports a case of EGFR-mutated adenocarcinoma of the lung that transitioned to squamous cell carcinoma in association with long-term EGFR-TKIs administration.
PMID: 33093956 [PubMed]

Source: Clinical Lung Cancer - October 25, 2020 Category: Cancer & Oncology Authors: Haruki T, Nakanishi A, Matsui S, Kidokoro Y, Kubouchi Y, Takagi Y, Taniguchi Y, Nakamura H Tags: Mol Clin Oncol Source Type: research